This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/pharmgkb/
n18http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/bindingdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/kegg-drug/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01021/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01021
rdf:type
n3:Drug
n3:description
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
n3:group
approved
n3:indication
Used in the treatment of oedema (including that associated with heart failure) and hypertension.
n3:manufacturer
n5:271B5473-363D-11E5-9242-09173F13E4C5 n5:271B5474-363D-11E5-9242-09173F13E4C5 n5:271B5471-363D-11E5-9242-09173F13E4C5 n5:271B5472-363D-11E5-9242-09173F13E4C5 n5:271B5477-363D-11E5-9242-09173F13E4C5 n5:271B5478-363D-11E5-9242-09173F13E4C5 n5:271B5475-363D-11E5-9242-09173F13E4C5 n5:271B5476-363D-11E5-9242-09173F13E4C5 n5:271B5470-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB01021 n19:DB01021
dcterms:title
Trichlormethiazide
adms:identifier
n7:46508880 n8:5560 n9:26998 n11:C07767 n12:D00658 n13:5359 n14:DB01021 n20:PA164752426
n3:mechanismOfAction
Trichlormethiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, Trichloromethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Trichloromethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Trichloromethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
n3:packager
n5:271B546F-363D-11E5-9242-09173F13E4C5 n5:271B546D-363D-11E5-9242-09173F13E4C5 n5:271B546E-363D-11E5-9242-09173F13E4C5 n5:271B546C-363D-11E5-9242-09173F13E4C5
n3:synonym
Naqua
n3:toxicity
Oral Rat LD<sub>50</sub> = 5600 mg/kg, oral Mouse LD<sub>50</sub> = 2600 mg/kg
n3:mixture
n10:271B546B-363D-11E5-9242-09173F13E4C5
n3:IUPAC-Name
n4:271B547E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5484-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5483-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5480-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5481-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5482-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B547C-363D-11E5-9242-09173F13E4C5 n4:271B5494-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5496-363D-11E5-9242-09173F13E4C5 n4:271B547A-363D-11E5-9242-09173F13E4C5 n4:271B547D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B547B-363D-11E5-9242-09173F13E4C5 n4:271B5497-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B5498-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:C03AA06
n3:H-Bond-Acceptor-Count
n4:271B548A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B548B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5485-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5486-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5488-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5487-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5489-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
133-67-5
n3:category
n3:containedIn
n22:271B5479-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5490-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5492-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5493-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5495-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B548F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B548E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5491-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B547F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B548C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B548D-363D-11E5-9242-09173F13E4C5